Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Nathan Cantoni"'
A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Autor:
Nathan Cantoni, Roberto Sommavilla, Patrick Seitz, Elisabeth Kulenkampff, Stefan Kahn, Jean-François Lambert, Adrian Schmidt, Reinhard Zenhaeusern, Stefan Balabanov
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European Leukemia Net (ELN) cri
Externí odkaz:
https://doaj.org/article/b6ab3f1aa7334dc6819ecce935003b14
Autor:
Franziska C. Adam, Jakub Szybinski, Jörg P. Halter, Nathan Cantoni, Friedel Wenzel, Katharina Leonards, Sime Brkic, Jakob R. Passweg, Ivo Touw, Julia E. Maxson, Sara C. Meyer
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 805-815 (2022)
Chronic neutrophilic leukemia (CNL) relates to mutational CSF3R activation with membrane proximal CSF3R mutations such as T618I as driver mutations, but the significance of truncating mutations is not clarified. In CNL, concomitant mutations promote
Externí odkaz:
https://doaj.org/article/7c6926b7e08c4f438dc34b200fa1a338
Autor:
Axel Rüfer, Hubert Angermann, Rudolf Benz, Nicolas Bonadies, Antonello Calderoni, Nathan Cantoni, Anna Efthymiou, Robert Escher, Geneviève Favre, Dorothea Friess, Andreas Gschwend, Andreas Himmelmann, Andreas Holbro, Peter Keller, Eirini Kouroupi, Thomas Lehmann, Nikolaus Pedarnig, Véronique Rigamonti, Kaveh Samii, Adrian Schmidt, Hans-Peter Schäfer, Roland Sperb, Georg Stüssi, Annette Winkler, Reinhard Zenhäusern, Jeroen S. Goede, on behalf of the SLIM-Registry Investigators
Publikováno v:
HemaSphere, Vol 6, Iss 7, p e741 (2022)
Externí odkaz:
https://doaj.org/article/96e57933677a4445bcd61d39ea571d5b
Autor:
Alicia Rovó, Nathan Cantoni, Kaveh Samii, Axel Rüfer, Giedre Koenen, Sandra Ivic, Davide Cavanna, Rudolf Benz
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0267342 (2022)
Aims of the studyThrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. This observational study aimed to
Externí odkaz:
https://doaj.org/article/f412851071b14047afa86e101bf9f96f
Autor:
Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas M. Schmitt, Nathan Cantoni, Clemens B. Caspar, Sonja Stettler, Roma Malval, Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos
Publikováno v:
Cancers, Vol 14, Iss 9, p 2191 (2022)
Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland. Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites over a one-year period starting on 1 March 20
Externí odkaz:
https://doaj.org/article/f6e3bc1300734e60ba06479ee90913ef
Autor:
Beatrice Drexler, Jakob R. Passweg, Alexandar Tzankov, Martin Bigler, Alexandre PA Theocharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz, Geneviève Favre, Pontus Lundberg, Ronny Nienhold, Andrea Fuhrer, Christine Biaggi, Markus G. Manz, Mario Bargetzi, Simon Mendez-Ferrer, Radek C. Skoda
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes
Externí odkaz:
https://doaj.org/article/8479aa021716446aad1f99447b3fef97
Autor:
Axel Rüfer, Christine Bapst, Rudolf Benz, Jens Bremerich, Nathan Cantoni, Laura Infanti, Kaveh Samii, Mathias Schmid, Jean-Paul Vallée
Publikováno v:
Swiss Medical Weekly, Vol 147, Iss 4546 (2017)
Hyperferritinaemia is a frequent clinical problem. Elevated serum ferritin levels can be detected in different genetic and acquired diseases and can occur with or without anaemia. It is therefore important to determine whether hyperferritinaemia is d
Externí odkaz:
https://doaj.org/article/c4d3afd29f3d4618b108c59f4a995f49
Publikováno v:
International Journal of Molecular Sciences, Vol 13, Iss 12, Pp 16020-16045 (2012)
Drug conjugates have been studied extensively in preclinical in vitro and in vivo models but to date only a few compounds have progressed to the clinical setting. This situation is now changing with the publication of studies demonstrating a signific
Externí odkaz:
https://doaj.org/article/b26cba26a253409d8773e48992ef07e7
Autor:
Claire Seydoux, Chakradhara Rao Satyanarayana Uppugunduri, Michael Medinger, Tiago Nava, Joerg Halter, Dominik Heim, Yves Chalandon, Urs Schanz, Gayathri Nair, Nathan Cantoni, Jakob R. Passweg, Marc Ansari
Publikováno v:
Bone Marrow Transplantation.
Busulfan (Bu) combined with cyclophosphamide (Cy) is commonly used as a myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). There is inter-individual variability of Bu pharmacokinetics (PK) and hence in to
Autor:
Urs Schanz, Claire Seydoux, Nathan Cantoni, Patrick Simon, Stavroula Masouridi Levrat, Sabine Gerull, Joerg Halter, Michael Medinger, Yves Chalandon, Gayathri Nair, Dominik Heim, Marc Ansari, Jakob Passweg
Publikováno v:
Annals of Hematology
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior